相关实验视频

Updated: Feb 26, 2026

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

纳米医学与免疫疗法相遇:转化化学抗原受体T细胞治疗固体瘤的治疗方法

Stephen O'Rourke¹, Nuo Xu², Hongjun Wang²

¹Department of Biological Sciences University of South Carolina Columbia SC 29208 USA.

|February 25, 2026

概括

化学抗原受体 (CAR) -T细胞疗法对血液癌症有希望,但与固体瘤作斗争. 纳米技术提供了潜在的解决方案,以增强CAR-T细胞疗法用于固体瘤治疗.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
纳米技术纳米技术

背景情况:

化学抗原受体 (CAR) -T细胞疗法 (CTT) 已经彻底改变了血液癌症治疗.
然而,CTT在固体瘤中的有效性受到瘤异质性和免疫抑制等因素的限制.

研究的目的:

审查CTT在固体瘤中的演变和挑战.
总结纳米技术支持的CTT对固体瘤的进展.

主要方法:

关于CAR-T细胞疗法和纳米技术应用的文献综述.
对固体瘤治疗的挑战和潜在解决方案的分析.

主要成果:

在血液性恶性瘤中,CTT实现了高缓解率.
固体瘤存在重大障碍,包括抗原异质性,T细胞透和免疫抑制微环境.

结论:

纳米技术具有很大的潜力,可以克服固体瘤中CTT的限制.
开发纳米技术支持的CTT可以带来更有效和个性化的癌症疗法.

关键词:

仿制性抗原受体T细胞疗法T细胞疗法纳米医药是一种纳米医药.固体瘤是一个固体瘤.有针对性的交付目标.瘤微环境是一个微环境.

更多相关视频

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.